MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$125,508K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Share-based compensation expense
Accounts payable
Depreciation and amortization
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Prepaid expenses and other asset...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2025-12-31
2025-09-30
2025-06-30
Net loss
-126,966
-69,900
-142,494
-
Depreciation and amortization
1,560
629
1,837
-
Amortization of right-of-use asset
354
147
342
-
Accretion of discounts on marketable securities
446
0
2,839
-
Share-based compensation expense
16,752
7,893
17,797
-
Loss on disposal of property and equipment
-78
-55
-841
-
Charge for purchase of in-process research and development assets
-
-
0
-
Charge for purchase of in-process research and development assets, including upon achievement of milestones
-
10,000
-
-
Prepaid expenses and other assets
11,995
42
3,447
-
Accounts payable
2,609
-2,277
-6,887
-
Accrued expenses and other current liabilities
-1,843
5,700
-1,167
-
Deferred revenue
0
0
-6,941
-
Operating lease liabilities
-433
-158
-8
-
Net cash used in operating activities
-120,330
-47,953
-142,966
-
Purchases of in-process research and development assets
9,014
0
6,246
-
Purchases of marketable securities
302,177
0
123,266
-
Maturities of marketable securities
0
0
200,000
-
Purchases of property and equipment
5,178
3,999
5,686
-
Net cash used in investing activities
-316,369
-3,999
64,802
-
Proceeds from public offerings
0
460,503
172,500
-
Proceeds from issuance of common stock under atm
-
0
45,897
-
Payment of offering costs
364
27,782
11,674
-
Proceeds from exercise of stock options
1,287
74
839
-
Proceeds from exercise of common stock warrants
-
0
0
-
Net cash provided by financing activities
923
432,795
207,562
-
Net (decrease) increase in cash and cash equivalents and restricted cash
-435,776
380,843
129,398
-
Cash and cash equivalents and restricted cash at beginning of period
653,692
144,086
144,086
-
Cash and cash equivalents and restricted cash at end of period
217,916
-
-
-
Cash and cash equivalents
217,706
-
-
143,876
Restricted cash
210
-
-
-
Total cash, cash equivalents, and restricted cash
217,916
653,692
272,849
144,086
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
stock options
$1,287K
Net cash provided by
financing activities
$923K
Canceled cashflow
$364K
Net (decrease)
increase in cash and cash...
-$435,776K
Canceled cashflow
$923K
Share-based compensation
expense
$16,752K
Accounts payable
$2,609K
Depreciation and
amortization
$1,560K
Amortization of right-of-use
asset
$354K
Loss on disposal of
property and equipment
-$78K
Payment of offering
costs
$364K
Net cash used in
investing activities
-$316,369K
Net cash used in
operating activities
-$120,330K
Canceled cashflow
$21,353K
Purchases of marketable
securities
$302,177K
Purchases of in-process
research and development...
$9,014K
Purchases of property and
equipment
$5,178K
Net loss
-$126,966K
Prepaid expenses and
other assets
$11,995K
Accrued expenses and
other current...
-$1,843K
Accretion of discounts on
marketable securities
$446K
Operating lease
liabilities
-$433K
Buy us a coffee
Immunome Inc. (IMNM)
Immunome Inc. (IMNM)